Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH6501 in Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
NCT06088654Phase 2Terminated
- Sponsor
- Innate Pharma
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of IPH6501 in non-Hodgkin lymphoma (NHL), sponsored by Innate Pharma. Primary endpoint: Safety and tolerability at 22 months. Started Mar 2024; status: terminated.
02
Drugs
IPH6501
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06088654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088654.